Close Menu

NEW YORK (GenomeWeb) — PrediLife said today that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

MammoRisk — used in conjunction with mammograms — is designed to determine breast cancer risk using a patient's age, breast density, family history, and breast biopsy history, as well as a polygenic score based on the analysis of disease-linked genetic variations from a saliva sample.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
31

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.